Avadel presents new clinical data from pivotal phase 3 rest-on trial supporting clinical benefit of ft218 in patients with narcolepsy at sleep 2021

Dublin, ireland, june 09, 2021 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a company focused on developing ft218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announced new post hoc analyses of data from the completed pivotal phase 3 rest-on clinical trial of ft218. the data were presented in three separate posters at sleep 2021, the 35th annual meeting of the associated professional sleep societies (apss), a joint meeting of the american academy of sleep medicine and the sleep research society.
AVDL Ratings Summary
AVDL Quant Ranking